

1st Quarter 2022 Results

1st Quarter 2022 Sales

\$23.4B | Worldwide Increased \uparrow **5.0%** | Excluding acquisitions/divestitures on an operational basis | Worldwide Increased \uparrow **7.9%***

Diluted Earnings Per Share

\$1.93 | Decreased \downarrow **(16.8)%**

Adjusted Diluted Earnings Per Share*

\$2.67 | Increased \uparrow **3.1%**




Joaquin Duato
Chief Executive Officer
Johnson & Johnson

“Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world. Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and innovative pipeline.”

\$3.6 Billion

Worldwide Consumer Health Sales²

Consumer Health worldwide reported sales decreased (1.5)%, but increased 0.8% operationally¹. Primary operational drivers:



TYLENOL



Motrin^{IB}

Imodium




Lubriderm

\$12.9 Billion

Worldwide Pharmaceutical Sales²

Pharmaceutical worldwide reported sales increased 6.3% or 9.3% operationally¹. Primary operational drivers:



Stelara[®]
(ustekinumab)

DARZALEX[®]
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

Tremfya[®]
(guselkumab)

Erleada[®]
(apalutamide) 60mg tablets

Upravi[®]
selexipag
tablets | 200-1600mg

INVEGA SUSTENNA[®]
paliperidone palmitate extended-release
orally disintegrating suspension

\$7.0 Billion

Worldwide MedTech Sales

MedTech worldwide reported sales increased 5.9% or 8.5% operationally¹. Primary operational drivers:



Electrophysiology

Contact Lens

Wound Closure

Surgical Vision

Hips

Biosurgery

Trauma

Endcutters

Knees

Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on April 19, 2022, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹Non-GAAP measure; excludes the impact of translational currency.

²Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in their respective regions.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, rereview the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on April 19, 2022, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.